Activity of decitabine combined with all- retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER).

Address: Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg.; Clinical Trials Unit, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg.; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen University, Aachen.; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover.; Department of Medicine III, Technical University of Munich, Munich, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Munich, München.; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; National Center of Tumor Diseases, NCT-Trial Center, German Cancer Research Center, Heidelberg.; Department of Internal Medicine III, University Hospital of Ulm, Ulm.; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tuebingen.; Department of Hematology/Oncology, Klinikum Luedenscheid, Luedenscheid.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Heidelberg, Heidelberg, Germany; Department of Medicine A, University Hospital of Münster, Münster.; Department of Hematology, Hospital Villingen-Schwenningen, Villingen-Schwenningen.; Department of Hematology, Oncology and Clinical Immunology, Heinrich- Heine-University, Faculty of Medicine, Düsseldorf, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Düsseldorf, Düsseldorf.; Department of Hematology and Oncology, Vivantes Klinikum Neukölln, Berlin.; Clinic for Oncology, Hematology and Palliative Medicine, Marien-Hospital Düsseldorf, Düsseldorf.; Department of Hematology and Oncology, Universitätsklinikum Jena, Klinik für Innere Medizin II, Jena.; Department of Hematology and Oncology, University Clinic Gießen/Marburg, Marburg.; Department of Internal Medicine III, Städtisches Klinikum Braunschweig, Braunschweig.; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Frankfurt, Frankfurt.; Krukenberg Cancer Center, University Hospital Halle, Halle.; Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Freiburg, Freiburg.; Institute for Surgical Pathology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg.; Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Department of Hematology/Oncology, Universitätsklinikum Augsburg, Augsburg.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg.; Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg. [email protected].